
Summary

In one aspect, there is provided a compound of the general formula (I)



formula (I)

and pharmaceutically acceptable salts or solvates thereof,

wherein

R^1 is aryl, heteroaryl, cycloalkyl, heterocyclyl or alkyl, which can be substituted by one or more substituents R'

Ar is aryl, cycloalkyl, heterocyclyl or heteroaryl, which can be substituted by one or more substituents R';


Z is H, halogen, -CR"O, -N(R")$_2$, -CN, -C(S)R", -N=C(R')$_2$, -CO_2R", -NR'CO_2R", -CONHR", -CON(R")$_2$, -COSR", -CSNHR", -CSN(R")$_2$, -SO_2-alkyl, -SO_2-haloalkyl, -SO_2NHR", -SO_2(NR")$_2$, amino or -SO_2R";

Y is H, halogen, haloalkyl, or alkyl, which can be substituted by one or more substituents R';


R' independently represents H, -CO_2R" –CONHR", -CR"O, -SO_2N(R")$_2$, -SO_2NHR", -NR"-CO-haloalkyl, -NO_2, -NR"-SO_2-haloalkyl, -NR"-SO_2-alkyl, -SO_2-alkyl, -NR"-CO-alkyl, -CN, alkyl, cycloalkyl, aminoalkyl, alkylamino, alkoxy, -OH, -SH, alkylthio, hydroxyalkyl, hydroxyalkylamino, halogen, haloalkyl, haloalkoxy, amino, heterocyclyl, aryl, haloaryl, haloarylalkyl, arylalkyl or heteroaryl;

R" independently represents H, haloalkyl, hydroxyalkyl, amino, alkoxy, -N=C(R')$_2$, -NR'-CO-R', -CR'O, -CO_2R', alkyl, cycloalkyl, aryl, haloaryl, haloarylalkyl, heteroaryl, heterocyclyl, arylalkyl or aminoalkyl, which are optionally substituted by one or more substituents R',


wherein the compound is not





,





,







































, or



In another aspect, there is provided a compound as defined herein for use as a medicament.

In another aspect, there is provided the use of the compounds of the formula (I) as defined herein, and of their pharmacologically tolerable salts in the manufacture of a medicament for treatment of a disease or a therapeutic indication in which the inhibition of interleukin- 17 (IL-17) and/or Interferon-γ (INF- γ) is beneficial.

Detailed Description